Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

Cancer - Tập 110 Số 12 - Trang 2614-2627 - 2007
Steven O’Day1, Omid Hamid1, Walter J. Urba2
1Medical Oncology, The Angeles Clinic and Research Institute, Santa Monica, California
2Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon

Tóm tắt

AbstractCancer immunotherapy centers on modulating the host's tumor‐directed immune response. One promising approach involves augmentation of cell‐mediated immunity by interrupting T‐cell pathways responsible for immune down‐regulation or tolerance. The discovery of cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and its role as a key negative regulator for T cells has prompted efforts to target this signaling molecule to improve cancer therapy. Activation, or ‘priming’, of naive T cells in response to tumor‐cell invasion comprises a dual‐signaling mechanism. Signal 1 requires tumor‐associated antigen recognition by the T‐cell receptor, while signal 2 occurs through binding of CD80 or CD86 (B7.1 of 2) on the antigen presenting cell (APC) with CD28 on the T cell. Importantly, there is a final step responsible for naturally occurring immune regulation; this occurs in response to competitive binding of CD80/CD86 on the APC by CTLA‐4 on the T cell. This ‘immune checkpoint’ interrupts signal 2 and inhibits the activated T cell. Targeting CTLA‐4 as an anticancer strategy: Following proof‐of‐concept studies in animals, fully human anti‐CTLA‐4 antibodies were developed and 2 are undergoing clinical evaluation. Ipilimumab and tremelimumab have shown promising antitumor activity, initially in patients with advanced melanoma. Class‐specific immune‐related adverse events (irAEs) were common and mostly transient and/or manageable. These events are thought to be mechanism‐of‐action‐related, indicating immune tolerance is broken; this relation may also explain the association between irAEs and response seen in several trials. Interruption of immune inhibitory pathways via CTLA‐4 blockade appears to be a promising strategy for cancer immunotherapy. Cancer 2007. © 2007 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.1136/bmj.1.5022.779

10.1126/science.1840703

10.1084/jem.183.3.725

10.1038/ni1102-991

Nagorsen D, 2003, Natural T cell immunity against cancer, Clin Cancer Res., 9, 4296

10.1126/science.1129139

10.1073/pnas.0509182102

Ishikawa T, 2003, Tumor‐specific immunological recognition of frameshift‐mutated peptides in colon cancer with microsatellite instability, Cancer Res., 63, 5564

10.1056/NEJMoa051424

10.1200/JCO.2004.10.041

Cutler CW, 2001, Dendritic cells: immune saviors or Achilles' heel?, Infect Immun., 69, 4703, 10.1128/IAI.69.8.4703-4708.2001

10.1016/S0952-7915(01)00300-4

10.1056/NEJMp068087

10.1615/CritRevImmunol.v18.i5.10

Janeway CA, 2001, Immunobiology: The Immune System in Health and Disease

Morse MA, 2005, Technology evaluation: ipilimumab, Medarex/Bristol‐Myers Squibb, Curr Opin Mol Ther., 7, 588

Kwon ED, 2003, The B7‐CD28 Family Molecules

10.1385/IR:29:1-3:197

10.1007/s00262-004-0593-x

10.2174/1568009054629681

10.1002/ijc.21775

10.1111/j.1600-065X.2006.00442.x

10.1016/j.coi.2006.01.011

10.1038/328267a0

10.1146/annurev.immunol.19.1.565

10.1016/S0065-2776(06)90008-X

10.1016/1074-7613(95)90125-6

10.1126/science.270.5238.985

10.1038/sj.gene.6363655

10.1677/jme.0.0310021

10.1210/jc.82.12.4130

10.1210/jc.2003-031854

10.1016/j.humimm.2004.04.007

10.1093/rheumatology/41.2.180

10.1200/JCO.2005.01.128

Faries MB, 2004, Post‐vaccination CTLA‐4 expression correlates inversely with survival in patients vaccinated with allogeneic melanoma cell vaccine, J Clin Oncol., 22, 2565, 10.1200/jco.2004.22.90140.2565

Korman A, 2005, Tumor immunotherapy: preclinical and clinical activity of anti‐CTLA4 antibodies, Curr Opin Investig Drugs., 6, 582

10.1084/jem.190.3.355

10.1073/pnas.95.17.10067

Hurwitz AA, 2000, Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA‐4 blockade, Cancer Res., 60, 2444

10.1016/j.vaccine.2003.10.048

10.1084/jem.194.6.823

10.1158/1078-0432.728.11.2

Mokyr MB, 1998, Realization of the therapeutic potential of CTLA‐4 blockade in low‐dose chemotherapy‐treated tumor‐bearing mice, Cancer Res., 58, 5301

Tchekmedyian S, 2002, MDX‐010 (human anti‐CTLA4): a phase I trial in malignant melanoma, J Clin Oncol., 21

Davis TA, 2002, MDX‐010 (human anti‐CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC), Proc Am Soc Clin Oncol, 21

10.1073/pnas.0830997100

10.1200/JCO.2005.01.109

Gomez‐Navarro J, 2006, Dose and schedule selection for the anti‐CTLA4 monoclonal antibody CP‐675,206 in patients (pts) with metastatic melanoma, J Clin Oncol., 24, s460

10.1002/cncr.21854

Bulanhagui CA, 2006, Phase I clinical trials of CP‐675,206: tumor responses are sufficient but not necessary for prolonged survival, J Clin Oncol., 24

Fischkoff SA, 2005, Durable responses and long‐term progression‐free survival observed in a phase II study of MDX‐010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma, J Clin Oncol., 23

10.1200/JCO.2005.06.205

10.1073/pnas.1533209100

10.1245/ASO.2005.03.536

Hamid O, 2007, Kinetics of response to ipilimumab (MDX‐010) in patients with stage III/IV melanoma, J Clin Oncol., 25

Weber J, 2007, The efficacy and safety of ipilimumab (MDX‐010) in subjects with unresectable stage III or IV malignant melanoma, J Clin Oncol., 25

Ribas A, 2007, Results of a phase II clinical trial of 2 doses and schedules of CP‐675,206, an anti‐CTLA4 monoclonal antibody in patients with advanced melanoma, J Clin Oncol., 25

Gomez‐Navarro J, 2007, Survival of patients with metastatic melanoma treated with the anti‐CTLA4 monoclonal antibody (mAb) CP‐675–206 in a phase I/II study, J Clin Oncol., 25

Fong L, 2007, Combination immunotherapy with GM‐CSF and CTLA‐4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells, J Clin Oncol., 25

Gerritsen W, 2007, Biochemical and immunologic correlates of clinical response in a combination trial of the GM‐CSF‐gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone‐refractory prostate cancer (mHRPC), J Clin Oncol., 25

Small E, 2006, Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX‐010) as a single agent or in combination with a single dose of docetaxel in patients with hormone‐refractory prostate cancer, J Clin Oncol., 24

Chung K, 2007, A phase II study of the anti‐CTLA4 monoclonal antibody (mAb), CP‐675–206, in patients with refractory metastatic adenocarcinoma of the colon or rectum, J Clin Oncol., 25

Weber JS, 2006, Phase II trial of extended dose anti‐CTLA‐4 antibody ipilimumab (formerly MDX‐010) with a multi‐peptide vaccine for resected stages IIIC and IV melanoma, J Clin Oncol., 24

10.1200/JCO.2005.04.5716

Antonia S, 2007, Natural history of diarrhea associated with the anti‐CTLA‐4 monoclonal antibody, J Clin Oncol., 25

10.1097/01.cji.0000178913.41256.06

ChenB PhillipsJ GreenbaumM et al.Efficacy of anti‐CTLA‐4 antibody in the SA1N tumor model when combined with dexamethasoneIn: American Association for Cancer Research Annual Meeting: Proceedings; 2007 April 14–18; Los Angeles CA. Philadelphia: AACR;2007. Abstract 2202.

10.1097/01.cji.0000208259.73167.58

10.1084/jem.192.2.303

10.4049/jimmunol.175.11.7746

10.1038/nrc2051

Ansell SM, 2006, Phase I/II study of ipilimumab (MDX‐010), an anti‐CTLA‐4 monoclonal antibody, in patients with follicular non‐Hodgkin lymphoma, Blood., 108, 772a, 10.1182/blood.V108.11.2729.2729

Yang JC, 2005, Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX‐010), J Clin Oncol., 23, s166

Thông tin
Thông tin xuất bản

Cancer

Tập 110 Số 12

2614-2627

Thông tin tác giả